ReviewCureus2024
Clinical Characteristics and Management of Drug-Induced Lupus Caused by Tumor Necrosis Factor Inhibitors: A Comprehensive Review.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF) inhibitor (TNFi) therapy, commonly used to treat autoimmune conditions, such as ankylosing spondylitis (AS), rheumatoid arthritis, and psoriatic arthritis, has been associated with the development of drug-induced lupus (DIL). While the incidence of TNFi-induced DIL is relatively rare, it typically presents with mild symptoms and can often be managed with continued therapy or medication switches. This review explores the clinical characteristics, management strategies, and outcomes of TNFi-induced DIL through a comprehensive examination of cases reported in the literature. The findings suggest that most patients develop anti-double-stranded DNA (anti-dsDNA) positivity without severe clinical manifestations, and major organ involvement is uncommon. Treatment strategies vary; some patients can maintain TNFi therapy without disease exacerbation, while others require alternative treatments. Further research is needed to refine management protocols and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.